Blood punction

PreclinicalBiologic

CCentral Hospital, Nancy, France

Blood punction is one of 78 biologic programs targeting Insulin resistance. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

MacroglobulinemiaActive, not recruiting

AneurysmActive, not recruiting

Insulin ResistancePreclinical

Active, not recruiting

MacroglobulinemiaPreclinical

Active, not recruiting

AneurysmPreclinical

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Insulin Resistance

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

15 2

Avandia

Jazz Pharmaceuticals

Approved

6 3

Glucophage

EMD Serono

Approved

17 4

Victoza

Novo Nordisk

Approved

1 5

Rozerem

Takeda

Approved

1 6

Niacor

AbbVie

Approved

1 7

Sovaldi

Gilead

Approved

1 8

Calciferol

Plaquenil

Tradjenta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

N/ANot yet recruiting

Insulin Resistance

NCT06825663

Clinical

Trials by Indication[1]

Aneurysm1 trial

Endoprosthesis Treatment Effects on Human Abdominal Aorta Aneurysms (AAA) Metabolic Activity

Completed·—·N/A·NCT01253252·45 enrolled

Macroglobulinemia1 trial

Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia

Completed·—·N/A·NCT02640287·55 enrolled

Cardiac Surgery1 trial

Study of the Relationship Between the Oxygenation State and Lung Ultrasound Score in Cardiac Surgery

Recruiting·—·N/A·NCT05470686·80 enrolled

Insulin resistance1 trial

Marker of Brain Insulin Resistance in AD Prognosis

Not yet recruiting·—·N/A·NCT06825663·122 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Blood punction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blood punction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blood punction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Central Hospital, Nancy, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCentral Hospital, Nancy, France

Blood punction

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Aneurysm1 trial

Macroglobulinemia1 trial

Cardiac Surgery1 trial

Insulin resistance1 trial

References

Drug Info

Quick Facts

Related News